Wilson M, Lucas A, Mendes D, Vyse A, Mikudina B, Czudek C, Ellsbury GF, Perdrizet J. Estimating the cost-effectiveness of switching to higher-valency pediatric pneumococcal conjugate vaccines in the United Kingdom. Vaccines (Basel). 2023 Jun 28;11(7):1168. doi: 10.3390/vaccines11071168
Oniangue-Ndza C, Strittmatter G, Lucas A, Wilson M, Kassahun S, Singh P. Pharmacoeconomic analysis of adjuvant nivolumab for patients with resected esophageal or gastroesophageal junction cancer in Switzerland. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S95. doi: 10.1016/j.jval.2022.09.464
Lucas A, Wilson M, Sings HL, Pugh S, Jones D, Farkouh R, Gessner B, Wasserman M. Estimating the vaccine effectiveness against serotype 3 for the 13-valent pneumococcal conjugate vaccine: a dynamic modeling approach. International journal of infectious diseases and therapy. 2019 Dec;4(4):56-66. doi: 10.11648/j.ijidt.20190404.12
Wilson M, Lucas A. Cost-effectiveness of Vedolizumab compared with Ustekinumab for the treatment of moderately-to-severely active Crohn's Disease in the United Kingdom. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain.
Lucas A, Wilson M, Brogan AJ, Wasserman M, Jones D, Hilton B, Farkouh R. In small doses: missing the booster dose in a reduced pneumococcal conjugate vaccination schedule. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.
Wasserman M, Lucas A, Jones D, Wilson M, Hilton B, Vyse A, Madhava H, Brogan A. Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK. Epidemiol Infect. 2018 Oct;146(14):1797-806. doi: 10.1017/S095026881800198X
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Lucas A, Wilson M, Wasserman M, Jones D, Vyse A, Slack M, Hilton B, Madhava H, Farkouh R. Dynamic transmission modeling of pneumococcal conjugate vaccine and potential dosing reduction in the United Kingdom. Poster presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 17, 2018. Melbourne, Australia.
Wasserman M, Lucas A, Wilson M, Farkouh R, Brogan A, Hilton B, Jones D. Dynamic transmission modeling to address infant pneumococcal conjugate vaccine schedule modifications. Poster presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 16, 2018. Melbourne, Australia.
Wilson M, Sander S, Kuti E, Lucas A. Cost offsets predicted with empagliflozin in patients with type 2 diabetes and established cardiovascular disease. Poster presented at the 2017 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 27, 2017. Denver, CO. [abstract] J Manag Care Spec Pharm. 2017 Mar; 23(3a):S46.